A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

NCT02516410 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-661 plus ivacaftor combination
DRUG: Ivacaftor
DRUG: Placebo (matched to VX-661 plus ivacaftor combination)
DRUG: Placebo (matched to ivacaftor)

Sponsor

Vertex Pharmaceuticals Incorporated